Microdose GLP-1 Protocol
US$ 24.74
retatrutide overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds Alarming rise in weight loss
Description
Avoid during pregnancy, and stop well before trying to conceive due to long drug half-lives
The dose can be further increased to 1 mg weekly and up to 2 mg weekly if needed for optimal glycaemic control, depending on individual response and tolerability
These titration schedules reflect trial-specific protocols and do not represent a licensed UK dosing regimen
Efpeglenatide, initially developed as a diabetes treatment, was licensed by Hanmi to the multinational pharmaceutical company Sanofi in 2015
Common side effects include nausea, gastrointestinal discomfort, and constipation
